51 results
424B5
STOK
Stoke Therapeutics Inc
28 Mar 24
Prospectus supplement for primary offering
5:15pm
impacts of the ongoing COVID-19 pandemic and its variants, the ability of STK-001 to treat the underlying causes of Dravet syndrome and reduce seizures
424B5
STOK
Stoke Therapeutics Inc
26 Mar 24
Prospectus supplement for primary offering
4:47pm
impacts of the ongoing COVID-19 pandemic and its variants, the ability of STK-001 to treat the underlying causes of Dravet syndrome and reduce seizures
8-K
EX-99.1
fl808qlf 372zdaxt
7 Aug 23
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
7:05am
8-K
EX-99.1
dulipk
4 May 23
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
7:05am
PRE 14A
v3f5z
17 Apr 23
Preliminary proxy
4:01pm
8-K
cff99tmbqspwoz3a76nq
2 Dec 22
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a
9:05am
8-K
EX-99.1
ngkgheqci13hdrx
2 Dec 22
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a
9:05am
8-K
EX-99.1
7bquggn g54k
14 Nov 22
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
7:05am
8-K
EX-99.1
h41vn6jv4nt59 k3gvnl
8 Aug 22
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
7:05am
8-K
EX-99.1
tstr6ssgx8m
10 May 22
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
7:05am